Innoviva Free Cash Flow 2012-2026 | INVA

Innoviva free cash flow from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Innoviva Annual Free Cash Flow
2025 195.81
2024 188.52
2023 140.65
2022 201.66
2021 363.81
2020 313.10
2019 257.45
2018 223.53
2017 141.75
2016 60.71
2015 10.12
2014 -266.41
2013 -217.34
2012 -130.10
2011 -91.97
Innoviva Quarterly Free Cash Flow
2026-06-30 86.52
2026-03-31 34.79
2025-12-31 195.81
2025-09-30 141.30
2025-06-30 92.69
2025-03-31 48.62
2024-12-31 188.52
2024-09-30 129.28
2024-06-30 80.86
2024-03-31 37.15
2023-12-31 140.65
2023-09-30 107.55
2023-06-30 63.83
2023-03-31 25.65
2022-12-31 201.66
2022-09-30 192.79
2022-06-30 177.12
2022-03-31 98.09
2021-12-31 363.81
2021-09-30 265.43
2021-06-30 168.72
2021-03-31 84.11
2020-12-31 313.10
2020-09-30 227.82
2020-06-30 153.26
2020-03-31 73.47
2019-12-31 257.45
2019-09-30 190.55
2019-06-30 133.15
2019-03-31 76.66
2018-12-31 223.53
2018-09-30 161.75
2018-06-30 101.64
2018-03-31 49.91
2017-12-31 141.75
2017-09-30 93.89
2017-06-30 50.40
2017-03-31 27.76
2016-12-31 60.71
2016-09-30 39.65
2016-06-30 19.70
2016-03-31 7.25
2015-12-31 10.12
2015-09-30 3.21
2015-06-30 0.55
2015-03-31 -1.62
2014-12-31 -266.41
2014-09-30 -126.67
2014-06-30 -105.60
2014-03-31 -107.26
2013-12-31 -217.34
2013-09-30 -91.30
2013-06-30 -49.75
2013-03-31 -32.37
2012-12-31 -130.10
2012-09-30 -105.59
2012-06-30 -77.46
2012-03-31 -42.43
2011-12-31 -91.97
2011-09-30 -65.71
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.527B $0.411B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $1085.319B 36.61
Johnson & Johnson (JNJ) United States $650.648B 24.86
AbbVie (ABBV) United States $466.363B 24.28
Merck (MRK) United States $362.354B 45.75
Roche Holding AG (RHHBY) Switzerland $344.965B 0.00
Novartis AG (NVS) Switzerland $267.847B 16.17
Novo Nordisk (NVO) Denmark $193.067B 10.76
Pfizer (PFE) United States $157.653B 9.07
Sanofi (SNY) France $102.990B 8.67
Bayer (BAYRY) Germany $54.077B 9.62